Beneath the ground, vast networks of fungi quietly support plant life and play an important role in regulating the planet’s…
Read More
Macrophage vs melanoma: immune cells attack live cancer cells in world-first footage
For the very first time, an international team of scientists has successfully captured live footage of macrophage immune cells actively…
Read More
First Blueprint of Human Skeletal Development Reveals Origins of Arthritis and Skull Conditions
In a landmark achievement for regenerative medicine and developmental biology, an international team of researchers has unveiled the first comprehensive…
Read More
Novo Nordisk Secures European Approval for Oral Wegovy, Bolstering First-Mover Advantage in Obesity Pill Market
Novo Nordisk has solidified its pioneering position in the burgeoning market for oral obesity medications with the European Commission’s marketing…
Read More
MSD Secures Landmark Approval for First Oral PCSK9 Inhibitor, Ushering in New Era for Cholesterol Management and Strategic Diversification
The pharmaceutical landscape has been significantly reshaped with MSD (Merck & Co.) achieving a monumental victory: the US Food and…
Read More
Fungal gene editing world-first points to promising cancer medicines
A groundbreaking development from the University of Pennsylvania (PA, USA) has introduced a sophisticated gene-editing platform, fPE7max, specifically optimized for…
Read More
The First Blueprint of Human Skeletal Development Maps the Cellular Origins of Arthritis and Congenital Bone Conditions
In a landmark achievement for regenerative medicine and developmental biology, researchers from the Wellcome Sanger Institute and their international collaborators…
Read More
World-first gene editing application unveils master regulator of human embryo development
The groundbreaking research, led by scientists at the University of Cambridge in the UK, represents a pivotal moment in developmental…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
In a landmark decision poised to reshape access to one of the world’s most sought-after medications, Health Canada has granted…
Read More
Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates
New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…
Read More
